TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
- PMID: 30610102
- DOI: 10.1158/1078-0432.CCR-18-3401
TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Abstract
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
©2019 American Association for Cancer Research.
Comment on
-
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res. 2019 Mar 15;25(6):1766-1773. doi: 10.1158/1078-0432.CCR-18-1943. Epub 2018 Sep 12. Clin Cancer Res. 2019. PMID: 30209161 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
